Literature DB >> 26684637

Clinic manifestations in granulomatosis with polyangiitis.

A Greco1, C Marinelli2, M Fusconi1, G F Macri3, A Gallo1, A De Virgilio1, G Zambetti1, M de Vincentiis1.   

Abstract

Granulomatosis with polyangiitis (GPA), formerly Wegener's granulomatosis (WG), is an uncommon immunologically mediated systemic small-vessel vasculitis that is pathologically characterised by an inflammatory reaction pattern (necrosis, granulomatous inflammation and vasculitis) that occurs in the upper and lower respiratory tracts and kidneys. Although the aetiology of GPA remains largely unknown, it is believed to be autoimmune in origin and triggered by environmental events on a background of genetic susceptibility.In Europe, the prevalence of GPA is five cases per 100,000 population, with greater incidence in Northern Europe. GPA can occur in all racial groups but predominantly affects Caucasians. Both sexes are affected equally. GPA affects a wide age range (age range, 8-99 years).Granulomatosis with polyangiitis is characterised by necrotising granulomatous lesions of the respiratory tract, vasculitis and glomerulonephritis. Classically, the acronym ELK is used to describe the clinical involvement of the ear, nose and throat (ENT); lungs; and kidneys. Because the upper respiratory tract is involved in 70-100% of cases of GPA, classic otorhinolaryngologic symptoms may be the first clinical manifestation of disease. The nasal cavity and the paranasal sinuses are the most common sites of involvement in the head and neck area (85-100%), whereas otological disease is found in approximately 35% (range, 19-61%) of cases.Diagnosis of GPA is achieved through clinical assessment, serological tests for anti-neutrophil cytoplasmic antibodies (ANCA) and histological analysis. The 10-year survival rate is estimated to be 40% when the kidneys are involved and 60-70% when there is no kidney involvement.The standard therapy for GPA is a combination of glucocorticoids and cyclophosphamide. In young patients, cyclophosphamide should be switched to azathioprine in the maintenance phase.A multidisciplinary approach, involving otorhinolaryngologists, oral and maxillofacial surgeons, oral physicians, rheumatologists, renal and respiratory physicians, and ophthalmologists, is necessary for the diagnosis and therapeutic treatment of GPA. ENT physicians have a determining role in recognising the early onset of the disease and starting an appropriate therapy.
© The Author(s) 2015.

Entities:  

Keywords:  Granulomatosis with polyangiitis; Wegener’s granulomatosis; autoimmunity; neurological symptoms; vascular symptoms; vasculitis; vertigo

Mesh:

Substances:

Year:  2015        PMID: 26684637      PMCID: PMC5806708          DOI: 10.1177/0394632015617063

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  49 in total

1.  Otological Wegeners granulomatosis: a diagnostic dilemma.

Authors:  M A Thornton; T J O'Sullivan
Journal:  Clin Otolaryngol Allied Sci       Date:  2000-12

2.  Histological findings in biopsies from patients with cytoplasmic-antineutrophil cytoplasmic antibody (cANCA)-positive Wegener's granulomatosis.

Authors:  S Maguchi; S Fukuda; M Takizawa
Journal:  Auris Nasus Larynx       Date:  2001-05       Impact factor: 1.863

Review 3.  Is Wegener's granulomatosis an autoimmune disease?

Authors:  P Hewins; J W Tervaert; C O Savage; C G Kallenberg
Journal:  Curr Opin Rheumatol       Date:  2000-01       Impact factor: 5.006

4.  Wegener's Granulomatosis of the ear.

Authors:  P J Bradley
Journal:  J Laryngol Otol       Date:  1983-07       Impact factor: 1.469

5.  Wegener's granulomatosis presenting as otitis media.

Authors:  B Nicklasson; N Stangeland
Journal:  J Laryngol Otol       Date:  1982-03       Impact factor: 1.469

6.  Ear involvement in Wegener's granulomatosis.

Authors:  H G Kempf
Journal:  Clin Otolaryngol Allied Sci       Date:  1989-10

7.  Lessons learnt in the management of Wegener's Granulomatosis: long-term follow-up of 60 patients.

Authors:  E L Sproson; N S Jones; M Al-Deiri; P Lanyon
Journal:  Rhinology       Date:  2007-03       Impact factor: 3.681

8.  Wegener's granulomatosis: cutaneous and oral mucosal disease.

Authors:  S F Patten; K J Tomecki
Journal:  J Am Acad Dermatol       Date:  1993-05       Impact factor: 11.527

9.  Early diagnosis of otologic Wegener's granulomatosis using the serologic marker C-ANCA.

Authors:  J D Macias; P A Wackym; B F McCabe
Journal:  Ann Otol Rhinol Laryngol       Date:  1993-05       Impact factor: 1.547

10.  Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis.

Authors:  C A Langford; M C Sneller; C W Hallahan; G S Hoffman; W A Kammerer; C Talar-Williams; A S Fauci; R S Lebovics
Journal:  Arthritis Rheum       Date:  1996-10
View more
  24 in total

Review 1.  Pituitary involvement in patients with granulomatosis with polyangiitis: case series and literature review.

Authors:  Yu Gu; Xuefeng Sun; Min Peng; Ting Zhang; Juhong Shi; Jiangfeng Mao
Journal:  Rheumatol Int       Date:  2019-06-15       Impact factor: 2.631

Review 2.  Anti-neutrophil cytoplasmic antibodies and their clinical significance.

Authors:  Supaporn Suwanchote; Muanpetch Rachayon; Pongsawat Rodsaward; Jongkonnee Wongpiyabovorn; Tawatchai Deekajorndech; Helen L Wright; Steven W Edwards; Michael W Beresford; Pawinee Rerknimitr; Direkrit Chiewchengchol
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

3.  [The role of the response to DNA damage in granulomatous diseases].

Authors:  Lea A R Fabry; Antigoni Triantafyllopoulou
Journal:  Z Rheumatol       Date:  2022-08-25       Impact factor: 1.530

Review 4.  2-deoxy-2[18F]fluoro-D-glucose positron emission tomography-computed tomography in rheumatological diseases.

Authors:  Manil Subesinghe; Shaheel Bhuva; Nikita Arumalla; Andrew Cope; David D'Cruz; Sujith Subesinghe
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

5.  Factors Affecting Dilation Interval in Patients With Granulomatosis With Polyangiitis-Associated Subglottic and Glottic Stenosis.

Authors:  Lena W Chen; Ioan Lina; Kevin Motz; Alexandra J Berges; Rafael Ospino; Philip Seo; Alexander T Hillel
Journal:  Otolaryngol Head Neck Surg       Date:  2021-04-13       Impact factor: 3.497

6.  Intractable chronic otitis media, rhinosinusitis and facial palsy: a case of active granulomatosis with polyangiitis.

Authors:  Kwee Yen Goh; Ross Bannon; Helin Nie Darat; Bhaskar Ram; Raghav C Dwivedi
Journal:  BMJ Case Rep       Date:  2020-09-07

7.  Case of disseminated histoplasmosis in a HIV-infected patient revealed by nasal involvement with maxillary osteolysis.

Authors:  A C Lehur; M Zielinski; J Pluvy; V Grégoire; S Diamantis; A Bleibtreu; C Rioux; A Picard; D Vallois
Journal:  BMC Infect Dis       Date:  2017-05-05       Impact factor: 3.090

8.  Tubular iron deposition and iron handling proteins in human healthy kidney and chronic kidney disease.

Authors:  Sanne van Raaij; Rachel van Swelm; Karlijn Bouman; Maaike Cliteur; Marius C van den Heuvel; Jeanne Pertijs; Dominic Patel; Paul Bass; Harry van Goor; Robert Unwin; Surjit Kaila Srai; Dorine Swinkels
Journal:  Sci Rep       Date:  2018-06-19       Impact factor: 4.379

9.  Pyoderma gangrenosum-like ulceration as a presenting feature of pediatric granulomatosis with polyangiitis.

Authors:  Rotem Semo Oz; Oluwakemi Onajin; Liora Harel; Rotem Tal; Tomas Dallos; Adena Rosenblatt; Lukas Plank; Linda Wagner-Weiner
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-05       Impact factor: 3.054

10.  Cutaneous Manifestations of Granulomatosis with Polyangiitis: A Case Series Study.

Authors:  Trinidad Montero-Vilchez; Antonio Martinez-Lopez; Luis Salvador-Rodriguez; Maria Del Carmen Ramírez-Barberena; Jesus Tercedor-Sanchez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  Acta Derm Venereol       Date:  2020-05-28       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.